A RANDOMIZED PHASE 2 OPEN LABEL STUDY OF NIVOLUMAB PLUS STANDARD DOSE BEVACIZUMAB VERSUS NIVOLUMAB PLUS LOW DOSE BEVACIZUMAB IN RECURRENT GLIOBLASTOMA (GBM)

被引：0
|
作者：
Ahluwalia, Manmeet [1 ]
Fallah, Jaleh [2 ]
Peereboom, David [3 ]
Schilero, Cathy [3 ]
Ali, Assad [3 ]
Forst, Deborah [4 ]
Wong, Eric [5 ]
Wen, Patrick [6 ]
Reardon, David [6 ]
机构：
[1] Case Western Reserve Univ, Lerner Coll Med, Cleveland Clin, Cleveland, OH 44106 USA
[2] Taussig Canc Inst, Cleveland, OH USA
[3] Cleveland Clin, Cleveland, OH 44106 USA
[4] Massachusetts Gen Hosp, Boston, MA 02114 USA
[5] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[6] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
NEURO-ONCOLOGY | 2019年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
RBTT-08
引用
收藏
页码：220 / 220
页数：1
相关论文
共 50 条
  • [21] A BAYESIAN ADAPTIVE RANDOMIZED PHASE II TRIAL OF BEVACIZUMAB VERSUS BEVACIZUMAB PLUS VORINOSTAT IN ADULTS WITH RECURRENT GLIOBLASTOMA FINAL RESULTS
    Puduvalli, Vinay
    Wu, Jing
    Yuan, Ying
    Armstrong, Terri
    Wu, Jimin
    Giglio, Pierre
    Xu, Jihong
    Colman, Howard
    Walbert, Tobias
    Raizer, Jeffrey
    Groves, Morris
    Iwamoto, Fabio
    Tran, David
    Avgeropoulos, Nicholas
    Paleologos, Nina
    Fink, Karen
    Peereboom, David
    Chamberlain, Marc
    Merrell, Ryan
    Penas-Prado, Marta
    Yung, W. K. Alfred
    Gilbert, Mark
    NEURO-ONCOLOGY, 2018, 20 : 13 - 13
  • [22] Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival
    Shah, Manish A.
    Cunningham, David
    Metges, Jean-Philippe
    Van Cutsem, Eric
    Wainberg, Zev
    Elboudwarej, Emon
    Lin, Kai-Wen
    Turner, Scott
    Zavodovskaya, Marianna
    Inzunza, David
    Liu, Jinfeng
    Patterson, Scott D.
    Zhou, Jingzhu
    He, Jing
    Thai, Dung
    Bhargava, Pankaj
    Brachmann, Carrie Baker
    Cantenacci, Daniel V. T.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (12)
  • [23] A randomized, open-label, multicenter, phase III study of high-dose vitamin C plus FOLFOX plus /- bevacizumab versus FOLFOX plus /- bevacizumab as first-line treatment in patients with unresectable metastatic colorectal cancer
    Wang, F.
    Xiao, J.
    Zhang, Y.
    Yuan, X.
    He, M.
    Fang, W.
    Zhang, Y.
    Wang, W.
    Hu, X.
    Ma, Z.
    Yao, Y.
    Zhuang, Z.
    Zhou, F.
    Ying, J.
    Yuan, Y.
    Zou, Q.
    Guo, Z.
    Wu, X.
    Jin, Y.
    Mai, Z.
    Guo, Y.
    Xu, R.
    ANNALS OF ONCOLOGY, 2022, 33 : S364 - S364
  • [24] SURVIVAL OUTCOMES WITH LOW-DOSE BEVACIZUMAB COMPARED TO STANDARD DOSE REGIMENS IN RECURRENT GLIOBLASTOMA
    Avgeropoulos, Nicholas
    Avgeropoulos, George
    Riggs, Garrett
    Reilly, Christopher
    NEURO-ONCOLOGY, 2013, 15 : 100 - 100
  • [25] EO2401 MICROBIOME DERIVED THERAPEUTIC VACCINE plus NIVOLUMAB, WITH/WITHOUT STANDARD CONTINUOUS, OR LOW-DOSE SYMPTOM DIRECTED, BEVACIZUMAB, IN RECURRENT GLIOBLASTOMA: PHASE 1-2 EOGBM1-18/ROSALIE STUDY
    Reardon, David
    Idbaih, Ahmed
    Vieito, Maria
    Tabatabai, Ghazaleh
    Stradella, Agostina
    Ghiringhelli, Francois
    Burger, Michael
    Mildenberger, Iris
    Herrlinger, Ulrich
    Gonzalez, Macarena
    GilMartin, Marta
    Renovanz, Mirjam
    Touat, Mehdi
    Wen, Patrick
    Wick, Antje
    Gouttefangeas, Cecile
    Maia, Ana
    Bonny, Chistophe
    Fagerberg, Jan
    Wick, Wolfgang
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A673 - A673
  • [26] Low-dose bevacizumab plus weekly irinotecan in recurrent glioblastoma multiforme, after failure of temozolamide: A phase II study.
    El Ghazaly, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [27] Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC.
    Kaseb, Ahmed Omar
    Pestana, Roberto Carmagnani
    Vence, Luis M.
    Blando, Jorge M.
    Singh, Shalini
    Ikoma, Naruhiko
    Vauthey, Jean-Nicolas
    Allison, James Patrick
    Sharma, Padmanee
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [28] NCCTG N1174: Phase I/comparative randomized phase (Ph) II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma (GBM) (Alliance).
    Galanis, Evanthia
    Anderson, S. Keith
    Butowski, Nicholas A.
    Hormigo, Adilia
    Schiff, David
    Tran, David Dinh
    Omuro, Antonio Marcilio Padula
    Jaeckle, Kurt A.
    Kumar, Shaji
    Kaufmann, Timothy J.
    Buckner, Jan C.
    Twohy, Erin
    Giannini, Caterina
    Wen, Patrick Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [29] Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC.
    Kaseb, Ahmed Omar
    Pestana, Roberto Carmagnani
    Vence, Luis M.
    Blando, Jorge M.
    Singh, Shalini
    Ikoma, Naruhiko
    Vauthey, Jean-Nicolas
    Allison, James Patrick
    Sharma, Padmanee
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [30] Cost saving analysis of reduced-dose versus standard-dose bevacizumab in recurrent glioblastoma
    Gleeson, Jack Patrick
    Greene, John Patrick
    Mullally, William J.
    Brady, Claire
    Goggin, Caitriona
    Dennehy, Colum
    Power, Derek Gerard
    Hennessy, Bryan
    Breathnach, Oscar S.
    Bambury, Richard Martin
    O'Reilly, Seamus
    Grogan, William
    Collins, Dearbhaile Catherine
    Morris, Patrick G.
    O'Mahony, Deirdre
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345